Company Overview of HemoShear, LLC
HemoShear, LLC, a biotechnology research company, develops and creates human-relevant systems that replicate the biology of organ systems and diseases in drug discovery and development. It conducts various experimental programs using human or animal primary cells; recreates in vivo hemodynamic conditions; cultures multiple cell types together to restore native biology; uses primary cells in physiologically accurate media conditions; creates physiologically relevant systems for understanding human responses in healthy and disease states; and provides human vascular systems, including artery systems, arteriole and microvascular systems, advanced inflammatory systems, atherosclerosis-prone cond...
1115 5th Street SW
Charlottesville, VA 22902
Founded in 2008
Key Executives for HemoShear, LLC
Chairman and Chief Executive Officer
Co-Founder, Chief Scientific Officer and Director
Co-Founder, Vice President of Research & Development and Director
Vice Chairman, Chief Financial Officer and Chairman of Audit Committee
Vice President of Operations
Compensation as of Fiscal Year 2014.
HemoShear, LLC Key Developments
HemoShear Completes First Phase of Development of Novel Cancer Drug Discovery Platform
Oct 9 14
HemoShear announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa, at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response. When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions. HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.
HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014
Jun 17 14
HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: Jun-24-2014, Vincent Aurentz, Chief Business Officer. Jun-25-2014, Brian R. Wamhoff, Co-Founder, Vice President of Research & Development and Director.
HemoShear, LLC Enters into R&D Collaboration with Medivir AB
Apr 23 14
HemoShear, LLC announced research collaboration with Medivir AB. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects of drug candidates on liver tissue using the Company's first-in-class human liver system. The HemoShear human liver system accurately replicates in vivo physiological conditions, enabling a more precise and definitive assessment of targets and drug candidates, drug-induced changes in biology and pharmacological responses. The collaboration with Medivir will also leverage and contribute to the set of drug exposure data HemoShear is creating as part of an ongoing program funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of NIH.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|